Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin

European Heart Journal

Volumn 28, Issue 12, 2007, Pages 1448-1453

  Lindgren, Peter ^a   Graff, Jennifer ^b   Olsson, Anders G ^c   Pedersen, Terje J ^d   Jönsson, Bengt ^e  

^a European Health Economics   (Sweden)

^b PFIZER INC   (United States)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Atorvastatin; Costs; Decision modelling; Heart disease; Secondary prevention

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; DOSE RESPONSE; FEMALE; FINLAND; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIMULATION; SURVIVAL TIME; SWEDEN; UNSPECIFIED SIDE EFFECT;

EID: 34548316230     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm020     Document Type: Article

References (24)

1. Jonsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-1007.
2. Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332- 336.
3. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-734.
4. Heart Protection Study Collaboration Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet 2005;365: 1779-1785.
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
7. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005;294: 2437-2445.
8. Nordic Centre for Classifications in Health Care. NordDRG Users' Manual 2006. http://www.nordclass.uu.se/verksam/norddrgmanual/ NordDRG_2006_NC.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338.
10. National Board of Health and Welfare. Statistical Databases. 2006, Socialstyrelsen, Stockholm.
11. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
12. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35:1095-1108.
13. Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001;10:621-635.
14. Lindgren P, Stenestrand U, Hambraeus K, Wallentin L, Jönsson B. PCI reduces utility loss after MI in Sweden. Eur Heart J 2006;27(Suppl 1): p. 773.
15. Lindgren P, Kahan T, Poulter N, Buxton M, Svarvar P, Dahlöf B, Jönsson B. Loss of utility and indirect costs caused by cardiovascular events in hypertensive patients: a health economic substudy of ASCOT. J Clin Hypertens 2006;8(Suppl. A):216A.
16. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001;22:919-925.
17. Efron B, Tibshirani R. An Introduction to the Bootstrap. 1993, New York: Chapman & Hall/CRC.
18. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000;9:623- 630.
19. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decisionmaking: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-528.
20. The National Board of Health and Welfare. Socialstyrelsens riktlinjer för hjärtsjukvård. Beslutsstöd för prioriteringar, 2004.
21. Statistics Sweden. Population Statistics. Statistiska centralbyrån, Stockholm, 2003; Available from: www.scb.se.
22. Johannesson M, Meltzer D, O'Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997;17:382-389.
23. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64.
24. Ekman M. Two Essays in Health Economics. Consumption and Production by Age with Emphasis on Health Care Expenditures and Economic Evaluation of Beta-Blocker Therapy in Heart Failure. Stockholm: Managerial Economics Section and Centre for Health Economics, Stockholm School of Economics; 2001.